EURURO Vol. 72 No. 6

Previous Page

Next Page

Page Background

Prostate Cancer Treated with First- and Second-line Abiraterone and Enzalutamide. J Clin Oncol 2017;35:2149–56. AR-V7 Testing: What’s in it for the Patient? Estimating the Clinical Utility of Blood-based AR-V7 Testing in Prostate Cancer http://dx.doi.org/10.1016/j.eururo.2017.06.032

J. Luo, B. Luber, H. Wang, E.S. Antonarakis

e172

Re: Eric A. Klein, Arnon Chait, Jason M. Hafron, et al. The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report. Eur Urol 2017;72:942–9 The Most Appropriate IsoPSA Cutoff for Diagnosis of Prostate Cancer http://dx.doi.org/10.1016/j.eururo.2017.06.028

P. Habibzadeh, F. Habibzadeh

e174

Reply to Parham Habibzadeh and Farrokh Habibzadeh’s Letter to the Editor re: Eric A. Klein, Arnon Chait, Jason M. Hafron, et al. The Single-parameter, Structure- based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.03.025. The Most Appropriate IsoPSA Cutoff for Diagnosis of Prostate Cancer http://dx.doi.org/10.1016/j.eururo.2017.07.020

E.A. Klein

e175

Re: Philipp Mandel, Felix Preisser, Markus Graefen, et al. High Chance of Late Recovery of Urinary and Erectile Function Beyond 12 Months After Radical Prostatectomy. Eur Urol 2017;71:848–50 http://dx.doi.org/10.1016/j.eururo.2017.06.033

J.H. Kim, B. Lee, B.I. Chung

e176

Reply to Jae Heon Kim, Bora Lee, and Benjamin I. Chung’s Letter to the Editor re: Philipp Mandel, Felix Preisser, Markus Graefen, et al. High Chance of Late Recovery of Urinary and Erectile Function Beyond 12 Months After Radical Prostatectomy. Eur Urol 2017;71:848–50 http://dx.doi.org/10.1016/j.eururo.2017.06.034

P. Mandel, D. Tilki

e177

Re: Philipp Mandel, Felix Preisser, Markus Graefen, et al. High Chance of Late Recovery of Urinary and Erectile Function Beyond 12 Months After Radical Prostatectomy. Eur Urol 2017;71:848–50 Late Recovery of Erectile Function After Radical Prostatectomy: Should We Modify the Way of Assessment? http://dx.doi.org/10.1016/j.eururo.2017.07.001

P. Capogrosso, F. Montorsi, A. Salonia

e179

Reply to Paolo Capogrosso, Francesco Montorsi, and Andrea Salonia’s Letter to the Editor re: Philipp Mandel, Felix Preisser, Markus Graefen, et al. High Chance of Late Recovery of Urinary and Erectile Function Beyond 12 Months After Radical Prostatectomy. Eur Urol 2017;71:848–50. Late Recovery of Erectile Function After Radical Prostatectomy: Should We Modify the Way of Assessment? http://dx.doi.org/10.1016/j.eururo.2017.07.002

P. Mandel, M. Graefen, H. Huland, D. Tilki

e180

Re: Sumanta K. Pal, Guru Sonpavde, Neeraj Agarwal, et al. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. Eur Urol 2017;72:557–64 http://dx.doi.org/10.1016/j.eururo.2017.07.009

Y. Lei, J. Mundhenk, C. Schwentner

e182

Congress Calendar

e185

Acknowledgement to Reviewers

e u r o p e a n u r o l o g y , vo l . 7 2 , n o . 6 , D e c emb e r 2 0 1 7

The illustrations on the cover of this issue are taken from the article by Giuseppe

Magistro, Christopher R. Chapple, Mostafa Elhilali, Peter Gilling, Kevin T. McVary, Claus

G. Roehrborn, et al, Emerging Minimally Invasive Treatment Options for Male Lower

Urinary Tract Symptoms, which is published on pp. 986–997 of this issue.